Literature DB >> 12228903

Hepatoblastoma: assessment of criteria for histologic classification.

Jon M Rowland1.   

Abstract

BACKGROUND: Comparison of outcomes in different clinicopathologic studies of hepatoblastoma requires reproducible histologic classification. This review examines the diagnostic criteria employed by different pathologists for the classification of subtypes of hepatoblastoma and identifies specific problem areas. PROCEDURE: A selected review of published literature is provided.
RESULTS: Published studies demonstrate that uniform criteria have not been applied in the classification of hepatoblastoma. These discrepancies hinder attempts to compare outcome data from different studies. Sampling error and potential treatment effects further complicate analysis of the published literature on the relationship between morphologic classification and outcome.
CONCLUSIONS: Standardized criteria are essential to allow reproducible histologic classification of hepatoblastoma. There is significant variation in diagnostic criteria used to define the major subtypes of hepatoblastoma in published studies. Additional potential problems are identified in sampling methods and treatment effects. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12228903     DOI: 10.1002/mpo.10171

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  13 in total

Review 1.  [Current status of diagnosis and treatment of hepatoblastoma].

Authors:  Purificación García-Miguel; Manuel López Santamaría
Journal:  Clin Transl Oncol       Date:  2005-08       Impact factor: 3.405

2.  Apoptotic protein expression, glycogen content, DNA ploidy and cell proliferation in hepatoblastoma subtyping and their role in prognostication.

Authors:  Anita Chopra; Venkateswaran K Iyer; Sandeep Agarwala; Sandeep R Mathur; Manju Aron; Siddharth Datta Gupta; Kusum Verma
Journal:  Pediatr Surg Int       Date:  2010-08-28       Impact factor: 1.827

3.  Malignant liver tumors in South African children: a national audit.

Authors:  S W Moore; A Davidson; G P Hadley; M Kruger; J Poole; D Stones; L Wainwright; G Wessels
Journal:  World J Surg       Date:  2008-07       Impact factor: 3.352

4.  Immunohistochemical features of the gastrointestinal tract tumors.

Authors:  Hannah H Wong; Peiguo Chu
Journal:  J Gastrointest Oncol       Date:  2012-09

5.  The differential expression of perilipin-2 in hepatoblastoma and its association with prognosis.

Authors:  Sadafumi Azukisawa; Jianbo Zheng; Xin Guo; Hiroki Ura; Yo Niida; Tohru Itoh; Sohsuke Yamada
Journal:  Histol Histopathol       Date:  2021-09-03       Impact factor: 2.303

6.  Identification of differentially expressed genes, lncRNAs and miRNAs which are associated with tumor malignant phenotypes in hepatoblastoma patients.

Authors:  Sida Liu; Fujing Xie; Xiaohong Xiang; Sinan Liu; Shunbin Dong; Kai Qu; Ting Lin
Journal:  Oncotarget       Date:  2017-10-31

7.  TUG1 Promoted Tumor Progression by Sponging miR-335-5p and Regulating CXCR4-Mediated Infiltration of Pro-Tumor Immunocytes in CTNNB1-Mutated Hepatoblastoma.

Authors:  Fujing Xie; Lianhai Zhang; Qing Yao; Liyu Shan; Jike Liu; Nanhai Dong; Jun Liang
Journal:  Onco Targets Ther       Date:  2020-04-14       Impact factor: 4.147

Review 8.  Advances in Understanding the LncRNA-Mediated Regulation of the Hippo Pathway in Cancer.

Authors:  Mengwei Wang; Tianwei Xu; Wenyan Feng; Junxia Liu; Zhaoxia Wang
Journal:  Onco Targets Ther       Date:  2021-04-07       Impact factor: 4.147

Review 9.  Hepatoblastoma: current understanding, recent advances, and controversies.

Authors:  Piotr Czauderna; Hanna Garnier
Journal:  F1000Res       Date:  2018-01-15

10.  A Human Organoid Model of Aggressive Hepatoblastoma for Disease Modeling and Drug Testing.

Authors:  James A Saltsman; William J Hammond; Nicole J C Narayan; David Requena; Helmuth Gehart; Gadi Lalazar; Michael P LaQuaglia; Hans Clevers; Sanford Simon
Journal:  Cancers (Basel)       Date:  2020-09-18       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.